Adeno-associated virus-mediated gene therapy in cardiovascular disease

Current Opinion in Cardiology

Volumn 30, Issue 3, 2015, Pages 228-234

  Hammoudi, Nadjib ^a   Ishikawa, Kiyotake ^a   Hajjar, Roger J ^a  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

adeno associated virus; arrhythmias; gene therapy; heart failure; sarcoplasmic reticulum calcium ATPase pump

Indexed keywords

BETA ADRENERGIC RECEPTOR; G PROTEIN COUPLED RECEPTOR KINASE 2; MICRORNA; PARVOVIRUS VECTOR; PEPTIDES AND PROTEINS; PHOSPHOPROTEIN PHOSPHATASE 1; PROTEIN PHOSPHATASE 1 INHIBITOR 1; S100A1 PROTEIN; SARCOPLASMIC RETICULUM CALCIUM TRANSPORTING ADENOSINE TRIPHOSPHATASE; SHORT HAIRPIN RNA; SMALL INTERFERING RNA; SMALL UNTRANSLATED RNA; SUMO 1 PROTEIN; UNCLASSIFIED DRUG;

ADENO ASSOCIATED VIRUS 1; ADENO ASSOCIATED VIRUS 6; ADENO ASSOCIATED VIRUS 8; ADENO ASSOCIATED VIRUS 9; ATRIOVENTRICULAR BLOCK; CARDIOVASCULAR DISEASE; CATECHOLAMINERGIC POLYMORPHIC VENTRICULAR TACHYCARDIA; CLINICAL TRIAL (TOPIC); ENZYME INHIBITION; GENE EXPRESSION; GENE TARGETING; HEART FAILURE; HUMAN; JET INJECTION; NONHUMAN; PRIORITY JOURNAL; REVIEW; RNA INTERFERENCE; SINUS NODE DISEASE; TRANS SPLICING; VIRAL GENE THERAPY; ANIMAL; ARRHYTHMIAS, CARDIAC; CARDIOVASCULAR DISEASES; DEPENDOPARVOVIRUS; GENE THERAPY; GENE VECTOR; GENETICS; PROCEDURES;

ANIMALS; ARRHYTHMIAS, CARDIAC; CARDIOVASCULAR DISEASES; DEPENDOVIRUS; GENETIC THERAPY; GENETIC VECTORS; HEART FAILURE; HUMANS;

EID: 84928536890     PISSN: 02684705     EISSN: 15317080     Source Type: Journal    
DOI: 10.1097/HCO.0000000000000159     Document Type: Review

References (52)

1. Go AS, Mozaffarian D, Roger VL, et al. Executive summary: heart disease and stroke statistics: 2014 update-a report from the American Heart Association. Circulation 2014; 129:399-410.
2. Writing Committee Members. Yancy CW, Jessup M, Bozkurt B, et al. 2013 ACCF/AHA guideline for the management of heart failure: A report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. Circulation 2013; 128:e240-e327.
3. Kawase Y, Ladage D, Hajjar RJ. Rescuing the failing heart by targeted gene transfer. J Am Coll Cardiol 2011; 57:1169-1180.
4. Zinn E, Vandenberghe LH. Adeno-associated virus: fit to serve. Curr Opin Virol 2014; 8:90-97.
5. Jaski BE, Jessup ML, Mancini DM, et al. Calcium upregulation by percutaneous administration of gene therapy in cardiac disease (CUPID Trial), a firstin-human phase 1/2 clinical trial. J Card Fail 2009; 15:171-181.
6. Jessup M, Greenberg B, Mancini D, et al. Calcium Upregulation by Percutaneous Administration of Gene Therapy in Cardiac Disease (CUPID): A phase 2 trial of intracoronary gene therapy of sarcoplasmic reticulum Ca2-ATPase in patients with advanced heart failure. Circulation 2011; 124:304-313.
7. Zsebo K, Yaroshinsky A, Rudy JJ, et al. Long-term effects of AAV1/SERCA2a gene transfer in patients with severe heart failure: Analysis of recurrent cardiovascular events and mortality. Circ Res 2014; 114:101-108.
8. Atchison RW, Casto BC, Hammon WM. Adenovirus-associated defective virus particles. Science 1965; 149:754-756.
9. Zincarelli C, Soltys S, Rengo G, Rabinowitz JE. Analysis of AAV serotypes 1-9 mediated gene expression and tropism in mice after systemic injection. Mol Ther 2008; 16:1073-1080.
10. Zaiss A-K, Liu Q, Bowen GP, et al. Differential activation of innate immune responses by adenovirus and adeno-associated virus vectors. J Virol 2002; 76:4580-4590.
11. Clark KR, Sferra TJ, Johnson PR. Recombinant adeno-associated viral vectors mediate long-term transgene expression in muscle. Hum Gene Ther 1997; 8:659-669.
12. Zhang Y, Yue Y, Li L, et al. Dual AAV therapy ameliorates exercise-induced muscle injury and functional ischemia in murine models of Duchenne muscular dystrophy. Hum Mol Genet 2013; 22:3720-3729.
13. Koo T, Popplewell L, Athanasopoulos T, Dickson G. Triple trans-splicing adeno-associated virus vectors capable of transferring the coding sequence for full-length dystrophin protein into dystrophic mice. Hum Gene Ther 2014; 25:98-108.
14. Jeune VL, Joergensen JA, Hajjar RJ, Weber T. Preexisting anti-adenoassociated virus antibodies as a challenge in AAV gene therapy. Hum Gene Ther Methods 2013; 24:59-67.
15. Greenberg B, Yaroshinsky A, Zsebo KM, et al. Design of a phase 2b trial of intracoronary administration of AAV1/SERCA2a in patients with advanced heart failure: The CUPID 2 trial (calcium up-regulation by percutaneous administration of gene therapy in cardiac disease phase 2b). JACC Heart Fail 2014; 2:84-92.
16. Qiao C, Li C, Zhao C, et al. K137R mutation on adeno-associated viral capsids had minimal effect on enhancing gene delivery in vivo. Hum Gene Ther Methods 2014; 25:33-39.
17. Ishikawa K, Fish KM, Tilemann L, et al. Cardiac I-1c overexpression with reengineered AAV improves cardiac function in swine ischemic heart failure. Mol Ther 2014; 22:2038-2045.
18. Chicoine LG, Montgomery CL, Bremer WG, et al. Plasmapheresis eliminates the negative impact of AAV antibodies on microdystrophin gene expression following vascular delivery. Mol Ther 2014; 22:338-347.
19. Raake PWJ, Schlegel P, Ksienzyk J, et al. AAV6.bARKct cardiac gene therapy ameliorates cardiac function and normalizes the catecholaminergic axis in a clinically relevant large animal heart failure model. Eur Heart J 2013; 34:1437-1447.
20. Katz MG, Fargnoli AS, Williams RD, et al. Safety and efficacy of high-dose adeno-associated virus 9 encoding sarcoplasmic reticulum Ca(2) adenosine triphosphatase delivered by molecular cardiac surgery with recirculating delivery in ovine ischemic cardiomyopathy. J Thorac Cardiovasc Surg 2014; 148:1065-1072.
21. Fargnoli AS, Katz MG, Williams RD, et al. A needleless liquid jet injection delivery method for cardiac gene therapy: A comparative evaluation versus standard routes of delivery reveals enhanced therapeutic retention and cardiac specific gene expression. J Cardiovasc Transl Res 2014; 7:756-767.
22. Winslow RL, Rice J, Jafri S, et al.Mechanisms of altered excitation-contraction coupling in canine tachycardia-induced heart failure, II: model studies. Circ Res 1999; 84:571-586.
23. Lompré A-M, Hajjar RJ, Harding SE, et al. Ca2 cycling and new therapeutic approaches for heart failure. Circulation 2010; 121:822-830.
24. Hadri L, Bobe R, Kawase Y, et al. SERCA2a gene transfer enhances eNOS expression and activity in endothelial cells. Mol Ther 2010; 18:1284-1292.
25. Hadri L, Kratlian RG, Benard L, et al. Therapeutic efficacy of AAV1.SERCA2a in monocrotaline-induced pulmonary arterial hypertension. Circulation 2013; 128:512-523.
26. Kho C, Lee A, Jeong D, et al. SUMO1-dependent modulation of SERCA2a in heart failure. Nature 2011; 477:601-605.
27. Schwartz RJ, Yeh ETH. Weighing in on heart failure: The role of SERCA2a SUMOylation. Circ Res 2012; 110:198-199.
28. Lee A, Jeong D, Mitsuyama S, et al. The role of SUMO-1 in cardiac oxidative stress and hypertrophy. Antioxid Redox Signal 2014; 21:1986-2001.
29. Tilemann L, Lee A, Ishikawa K, et al. SUMO-1 gene transfer improves cardiac function in a large-animal model of heart failure. Sci Transl Med 2013; 5:211ra159.
30. Kraus C, Rohde D, Weidenhammer C, et al. S100A1 in cardiovascular health and disease: closing the gap between basic science and clinical therapy. J Mol Cell Cardiol 2009; 47:445-455.
31. Most P, Seifert H, Gao E, et al. Cardiac S100A1 protein levels determine contractile performance and propensity toward heart failure after myocardial infarction. Circulation 2006; 114:1258-1268.
32. Pleger ST, Shan C, Ksienzyk J, et al. Cardiac AAV9-S100A1 gene therapy rescues postischemic heart failure in a preclinical large animal model. Sci Transl Med 2011; 3:92ra64.
33. Weber C, Neacsu I, Krautz B, et al. Therapeutic safety of high myocardial expression levels of the molecular inotrope S100A1 in a preclinical heart failure model. Gene Ther 2014; 21:131-138.
34. Haghighi K, Bidwell P, Kranias EG. Phospholamban interactome in cardiac contractility and survival: A new vision of an old friend. JMol Cell Cardiol 2014; 77:160-167.
35. Kranias EG, Hajjar RJ. Modulation of cardiac contractility by the phospholamban/SERCA2a regulatome. Circ Res 2012; 110:1646-1660.
36. Pathak A, del Monte F, Zhao W, et al. Enhancement of cardiac function and suppression of heart failure progression by inhibition of protein phosphatase. Circ Res 2005; 96:756-766.
37. Fish KM, Ladage D, Kawase Y, et al. AAV9.I-1c delivered via direct coronary infusion in a porcine model of heart failure improves contractility and mitigates adverse remodeling. Circ Heart Fail 2013; 6:310-317.
38. Dzau VJ, Braun-Dullaeus RC, Sedding DG. Vascular proliferation and atherosclerosis: new perspectives and therapeutic strategies. Nat Med 2002; 8:1249-1256.
39. Lipskaia L, Bobe R, Chen J, et al. Synergistic role of protein phosphatase inhibitor 1 and sarco/endoplasmic reticulum Ca2-ATPase in the acquisition of the contractile phenotype of arterial smooth muscle cells. Circulation 2014; 129:773-785.
40. Lohse MJ, Engelhardt S, Eschenhagen T. What is the role of beta-adrenergic signaling in heart failure? Circ Res 2003; 93:896-906.
41. Brodde OE. Beta-adrenoceptors in cardiac disease. Pharmacol Ther 1993; 60:405-430.
42. Williams ML, Hata JA, Schroder J, et al. Targeted beta-adrenergic receptor kinase (betaARK1) inhibition by gene transfer in failing human hearts. Circulation 2004; 109:1590-1593.
43. Piras BA, O'Connor DM, French BA. Systemic delivery of shRNA by AAV9 provides highly efficient knockdown of ubiquitously expressed GFP in mouse heart, but not liver. PLoS One 2013; 8:e75894.
44. Huang BS, Chen A, Ahmad M, et al. Mineralocorticoid and AT1 receptors in the paraventricular nucleus contribute to sympathetic hyperactivity and cardiac dysfunction in rats post myocardial infarct. J Physiol 2014; 592 (Pt 15): 3273-3286.
45. Van Rooij E. The art of microRNA research. Circ Res 2011; 108:219-234.
46. Karakikes I, Chaanine AH, Kang S, et al. Therapeutic cardiac-targeted delivery of miR-1 reverses pressure overload-induced cardiac hypertrophy and attenuates pathological remodeling. J Am Heart Assoc 2013; 2:e000078.
47. Ganesan J, Ramanujam D, Sassi Y, et al. MiR-378 controls cardiac hypertrophy by combined repression of mitogen-activated protein kinase pathway factors. Circulation 2013; 127:2097-2106.
48. Wahlquist C, Jeong D, Rojas-Muñ oz A, et al. Inhibition of miR-25 improves cardiac contractility in the failing heart. Nature 2014; 508:531-535.
49. Denegri M, Bongianino R, Lodola F, et al. Single delivery of an adeno-associated viral construct to transfer the CASQ2 gene to knock-in mice affected by catecholaminergic polymorphic ventricular tachycardia is able to cure the disease from birth to advanced age. Circulation 2014; 129:2673-2681.
50. Boink GJJ, Robinson RB. Gene therapy for restoring heart rhythm. J Cardiovasc Pharmacol Ther 2014; 19:426-438.
51. Hu Y-F, Dawkins JF, Cho HC, et al. Biological pacemaker created by minimally invasive somatic reprogramming in pigs with complete heart block. Sci Transl Med 2014; 6:245ra94.
52. Boink GJJ, Duan L, Nearing BD, et al. HCN2/SkM1 gene transfer into canine left bundle branch induces stable, autonomically responsive biological pacing at physiological heart rates. J Am Coll Cardiol 2013; 61:1192-1201.